Results 261 to 270 of about 83,135 (307)
Some of the next articles are maybe not open access.
The bipolar diathesis of treatment-resistant major depressive disorder
International Journal of Psychiatry in Clinical Practice, 2008Objective. In this study, we determined the prevalence of bipolarity in patients with treatment-resistant depression (TRD) by investigating demographic and clinical characteristics, diagnostic subtypes and illness outcome of patients with resistant depression. Methods.
Young Sup, Woo +4 more
openaire +2 more sources
Pramipexole augmentation in treatment-resistant major depressive disorder
Expert Review of Neurotherapeutics, 2013Evaluation of: Cusin C, Iovieno N, Iosifescu DV et al. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. J. Clin. Psychiatry 74(7), e636-e641 (2013). To overcome limited efficacy in antidepressants, clinicians may choose augmentation, switching to a different ...
openaire +2 more sources
The ‘Dalhousie Serotonin cocktail’ for treatment-resistant major depressive disorder
Journal of Psychopharmacology, 2001We describe the successful treatment of five patients with treatment-resistant major depressive disorder (TR-MDD) with a combination pharmacotherapy of pindolol, tryptophan and nefazodone. Five TR-MDD outpatients who had previously not responded to at least four different antidepressant medication trials were initiated on 300 mg/day of nefazodone, 7.5
S M, Dursun, S, Devarajan, S, Kutcher
openaire +2 more sources
Mismatch negativity in treatment-resistant depression and borderline personality disorder
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010Cognitive dysfunctions, such as attentional impairment, are central features of both treatment-resistant depression (TRD) and borderline personality disorder (BPD). The treatment failure of TRD due to its comorbidity with BPD is debated in the literature.
Wei, He +7 more
openaire +2 more sources
Use of atypical antipsychotics for treatment-resistant major depressive disorder
Current Psychiatry Reports, 2008Despite the progressive increase in the number of pharmacologic agents with potential antidepressant activity, many patients suffering from major depressive disorder (MDD) continue to be symptomatic. Clearly, an urgent need exists to develop safer, better tolerated, and more effective treatments for MDD.
George I, Papakostas, Richard C, Shelton
openaire +2 more sources
Hypothalamo-Pituitary-Adrenal Axis in Depressive Disorders and Treatment Resistance
Psikhiatriya, 2023Background: hypothalamo-pituitary-adrenal (HPA) axis plays an important role in the pathogenesis of depression. Patterns of HPA functioning depend on both biologic factors and psychological background, which, taken together, may increase the risk of depression later on.
O. A. Yunilayne +2 more
openaire +1 more source
Augmentation of antidepressants with perospirone for treatment-resistant major depressive disorder
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009We examined the efficacy and tolerability of perospirone, a dopamine D2 and 5-HT2A receptor antagonist and a partial 5-HT1A receptor agonist, in the augmentation of antidepressant treatment of partially responding and nonresponding patients with major depressive disorder.
Yasushi, Sato +4 more
openaire +2 more sources
Ketamine: Clinical Studies in Treatment-Resistant Depressive Disorders
2016Since the first report of a robust antidepressant effect of a sub-anesthetic dose of ketamine in 2000, studies have repeatedly confirmed its therapeutic benefits in major depressive disorder (MDD) as well as in depressive episodes in patients with bipolar disorder (BD). Two features of the antidepressant response to ketamine make it striking: first, it
Pierre Blier, Jean Blier
openaire +1 more source
Treatment-resistant major depressive disorder and assisted dying: response to comments
Journal of Medical Ethics, 2015The commentaries responding to our article on treatment-resistant depression and assisted dying focus on the following issues: epistemological questions about death, patient competence, the role of doctors, the moral basis of the right to an assisted death, safety and security of patients, and questions about various cases that occurred in the ...
Schuklenk, Udo, van de Vathorst, Suzanne
openaire +3 more sources
Commentary on ‘Treatment-resistant major depressive disorder and assisted dying’
Journal of Medical Ethics, 2015Schuklenk and van de Vathorst (henceforth “the authors”) make the following starting assumption, which I will accept: that it is ethically permissible for doctors to assist suicide and it is permissible for those competent patients with terminal somatic diseases (such as inoperable stage IV cancer) or non-terminal but untreatable debilitating diseases (
openaire +2 more sources